HEALTH PROFESSIONAL · SOURCE READING

Rituximab with or without chemotherapy

Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Indolent Stage I and Indolent, Contiguous Stage II B-Cell Non-Hodgkin Lymphoma / Treatment Options for Indolent Stage I and Indolent, Contiguous Stage II B-Cell NHL

When radiation therapy is contraindicated, or when an alternative treatment is preferred, patients with symptomatic disease who require therapy may receive rituximab with or without chemotherapy (as outlined below for more advanced-stage patients).[11] The value of adjuvant treatment with radiation to decrease relapse, plus rituximab (an anti–CD20 monoclonal antibody) either alone or in combination with chemotherapy, has been extrapolated from trials of patients with advanced-stage disease and has not been confirmed.[12,13]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice